During this exercise of searching and reading research papers, we found that researchers in neuroblastoma are looking for alternatives of traditional 2D culture. It is may be slow at the moment but the interest is there.
3D neuroblastoma models worked well in both validating known chemotherapies and screening new. The concepts and materials that were initially developed for bone or tissue regeneration can be used to a miniature model of neuroblastoma.
3D tissue-engineered models can accelerate drug discovery and development, reducing the use of animals in preclinical studies.
Here we go. Our first attempt to bio print neuroblastoma cells using Rastrum technology.
A compact pink oven-like device with a user-friendly interface and ‘magical’ disperse of cells and 3D environments. We bioprinted two types of neuroblastoma cells. One-easily forming clusters or tight groups and the other with high individualism in two types of homes: friendly and unfriendly. ‘Friendly’ homes have lots of clues to help cells to attach and grow. ‘Unfriendly’ homes have just a 3D niche aka house without furniture. Let’s see which homes cells like most.
Now, when my team has expanded, it is so easy to come up with fundraising ideas and then develop one in a well-rounded event. In February, we ran Hot Chocolate Morning to raise awareness in childhood cancer and celebrate the International Childhood Cancer Awareness Day. We have an entire month of September to make this disease visible. It was the first time for some of my team members.
“Last Friday, I got to take part in my first fundraising event at the Royal College of Surgeons in Ireland. Our team hosted a waffle morning for #childhoodcancerawarenessmonth and we are delighted to have raised €403.85 thanks to everyone’s generous donations! Our fundraising does not stop here, in just a few weeks time all 7 of us will be taking on the 8km Hell and Back challenge to raise more awareness and funds for our four chosen charities: CMRF Crumlin, Neuroblastoma UK, and the Conor Foley Neuroblastoma Cancer Research Foundation. We hope everyone enjoyed their little Friday treat!” Catherine Murphy, PhD student funded by Neuroblastoma UK
I have started a new chapter in my research career by joining the Department of Anatomy and Regenerative Medicine as a StAR Research Lecturer. By a coincidence, it has happened on the first day of Childhood Cancer Awareness Month. It might be symbolic.
The new start requires fresh ideas. Now, the new chapter is called Cancer Bioengineering Group. Exciting times ahead!
This Friday the 13th of September the Cancer-Bioengineering research group will be hosting a ‘Waffle Morning’ in honour of Childhood Cancer Awareness Month.
Pop into the ground floor staff common room from 8.30am to enjoy some delicious freshly made waffles and support the wonderful charities; CMRF Crumlin, NCRC, CFNCRF and NBUK.
We promise to bake 3D waffle engineered scaffolds and populate them with marshmallows, berries, cream and Nutella!
We celebrate Childhood Cancer Awareness Month every September. This is our chance to talk about this cancer, the patients and their families and what can be done to make a change.
Together with Prof Richard Arnett we asked a question – how intense is communication about neuroblastoma/childhood cancer on Twitter. There were 52126 neuroblastoma tweets in 69 days. Is it a big number?
Yellow dotes represent tweets. The intensity of yellow reflects the number of tweets per account. Many of them formed isolated communities with no connections. A few reach out. And this is very sad, it means that these communities do not interact with each other.
Communities have to come together then they will be heard. The Childhood Cancer Awareness months is a great opportunity to do it.
Exciting times ahead for my team – to study neuroblastoma – immune cells interaction. This 3 years project is funded by Neuroblastoma UK to support the interdisciplinary collaboration between experts in fields of neuroblastoma biology, immunology and tissue engineering from Royal College of Surgeons in Ireland, Trinity College Dublin and Queen Mary University London.
Catherine will grow different neuroblastoma cells together with immune cells using a 3D printing technology. She will travel to Queen Mary University London and learn how to do 3D tumour bioprinting. This technology allows the generation of reproducible scaffolds that replicate the architecture of tumour tissues as seen in patients. She will use RCSI/AMBER facilities to optimise this model here and to study how immune cells recognise cancer cells, attack and eventually kill them. This experimental model will help us to advance current immunotherapies and develop more effective treatments for neuroblastoma.
An interesting idea or research question is always motivational. But it is a sketch till you get means to answer them. We, scientists, have to shape them into a proposal showing that we know limitations and have plans B & C if things go differently to planned. Then we apply for funding here and there… and many many times. The number of rejections makes us stronger – I hope. But one day, the idea may hit it right. So, it has happened to me recently and this SFI Award brings so needed fuel to study neuroblastoma.
The development and approval of new oncology drugs are very slow processes. This is mainly due to the big differences in the physiology of cancer cells grown on plastic and in the native microenvironment. Tissue engineering of tumour systems has a great potential to bridge this gap. This Award will help to advance our 3D tissue-engineered of neuroblastoma, that can be used in testing new drugs and new combinations of existing drugs.
In particular, we will adapt the 3D model to screen different immunotherapies. This treatment option is very attractive both for adults and children because of its specificity and reduced side effects compared to chemotherapy, the current standard of care.
This Award will help my team to get a better understanding how neuroblastoma cells interact with the body environment, particularly with the immune system and how we can use the knowledge to develop new treatments and improve the patient outlook.
Across countries and continents, we are celebrating International Childhood Cancer Day (ICCD).We do it to raise awareness tto raise awareness of childhood cancer, its consequences for children and their parents and make it as a priority for Governments and research.
My team research is focused on neuroblastoma biology. This is a solid tumour of undeveloped nerves. Some forms of neuroblastoma spread quickly and become very aggressive and challenging to treat. We are searching for the weaknesses that can be targeted with drugs.
A guessing game was a part of the event. Everyone had a chance to guess how many marshmallows fitted in the cell culture flask T75. The guesses ranged from as low as 95 to as high as 500. Fortunately, one of the participants gave an absolutely correct answer. Micheal Flood put on 173 and won. Her fantastic ability to guess is incredible! Congratulations!!! Well done to all!
We raised 698.91 Euros for childhood cancer research! We thank everyone who came along and supported the Hot Chocolate Morning & the International Childhood Cancer Day 2019!
Many special thanks go to Amorino for delicious Italian hot chocolate & tasty bites contributors!
Today marks the start of Childhood Cancer Awareness Month.
The cause of childhood cancers is believed to be due to faulty genes in stem cells that give rise to nerves, skin, blood and other body tissues. For some unknown reasons, the faulty genes can sit quiet and show their ‘bad’ character after birth and programme the cells into cancer cells.
So, there is no evidence that links lifestyle or environmental risk factors to the development of childhood cancer, which is opposite to many adult’s cancers.
Every 100th cancer patient is a child. Cancer is the 2nd most common cause of death among children after accidents.
Children are not little adults and so their cancer. Some childhood cancers have a good outlook and successful protocol of treatments. However, some of the cancers do not respond to the known drugs, or if respond cancer cells find the way to develop resistance and come back being more aggressive. Among theme are some forms of brain tumours, neuroblastoma and sarcomas; cancers developing in certain age groups and/or located within certain sites in the body, along with acute myeloid leukaemia (blood cancer). Children with a rare brain cancer – diffuse intrinsic pontine glioma survive less than 1 year from diagnosis. Children with soft tissue tumours have 5-year survival rates ranging from 64% (rhabdomyosarcoma) to 72%(Ewing sarcoma). Less than50% of children with the aggressive form of neuroblastoma will live beyond 5 years with current treatment strategies.
For majority of children who do survive cancer, the battle is never over. Over 60% of long‐term childhood cancer survivors have a chronic illness as a consequence of the treatment; over 25% have a severe or life-threatening illness.
The most common types of childhood cancer are:
Leukaemia and lymphoma (blood cancers)
Brain and other central nervous system tumours
Muscle cancer (rhabdomyosarcoma)
Kidney cancer (Wilms tumour)
Neuroblastoma (tumour of the non-central nervous system)
Bone cancer (osteosarcoma)
Testicular and ovarian tumours (gonadal germ cell tumours)
Another year, another Research Summer School students. We are hosting 4 students (Jessica, Dawn, Dola, and Jeff) this year. Some of them will be medical doctors, another will do research after the graduation. For them, the 8-weeks lab placement is a window into the reality of the everyday science. How cancer cells look? How do they grow? Where do we store them? How do we know that we have identified a new drug or a new target to study further? Do researchers have a sense of humour? Do they like donuts?
We have already said Good Bye to Jessica. Dola and Dawn’s projects are coming to an end this week, while Jeff is staying till the end of August.